Results 61 to 70 of about 19,188,679 (307)
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak +9 more
wiley +1 more source
Type of chemotherapy in second-line treatment.
Type of chemotherapy in second-line treatment.
Magdalena Piróg (6281519) +10 more
core +1 more source
ABSTRACT Purpose To explore caregivers' experiences and perceptions of the nutritional challenges faced by children and adolescents undergoing cancer treatment, including oral intake and the use of nutritional support. Methods This was a qualitative study based on focus groups with parents and caregivers at a Brazilian pediatric oncology hospital ...
Danyelle Apparecida Balsamão Marques +5 more
wiley +1 more source
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Channing J Paller, Emmanuel S AntonarakisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USAAbstract: Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became ...
Channing J Paller +1 more
doaj
Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes. [PDF]
BACKGROUND After first-line antiretroviral therapy (ART) failure, the importance of change in nucleoside reverse transcriptase inhibitor (NRTI) in second-line is uncertain due to the high potency of protease inhibitors used in second-line. SETTING
Horsburgh, C Robert +41 more
core +2 more sources
ABSTRACT Background Heavy menstrual bleeding (HMB) is a common condition among adolescents and young adults (AYAs) and is the leading cause of iron deficiency anemia (IDA) in this population. Growing evidence suggests that social determinants of health (SDOH) influence menstrual bleeding patterns, access to care, and treatment. However, no studies have
Maria Carter‐Febres +6 more
wiley +1 more source
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. [PDF]
BACKGROUND Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts.
Porta C. +40 more
core +2 more sources
Organoids in pediatric cancer research
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide, with adenocarcinoma being the most common histological subtype.
Niki Karachaliou, Rafael Rosell
doaj +1 more source
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. [PDF]
To view this article, click on "Additional Links".CONTEXT: Long-term antiretroviral therapy (ART) use in resource-limited countries leads to increasing numbers of patients with HIV taking second-line therapy. Limited access to further therapeutic options
Mar Pujades-Rodríguez +6 more
core +1 more source

